Market Place
Sourcing Support
Humanetics Advances Radiation Protection Drug with New Study
30 Oct 2024 //
BUSINESSWIRE
Humanetics Presents At Department Of Defense Science Meeting
03 Oct 2024 //
BUSINESSWIRE
Humanetics to Participate in the Bio Investor Forum in San Francisco
01 Oct 2024 //
BUSINESSWIRE
USU Grants Humanetics For Radiation Countermeasure Development
08 Aug 2024 //
BUSINESSWIRE
Humanetics To Present At BIO International Convention
31 May 2024 //
BUSINESSWIRE
Humanetics Corporation to Present at Investor and Partnering Conferences
07 Feb 2024 //
BUSINESSWIRE
Humanetics Corporation Appoints Dr. Colin Chinn as Chief Medical Officer
14 Nov 2023 //
BUSINESSWIRE
Humanetics Receives Funding to Study New Drug for Idiopathic Pulmonary Fibrosis
24 Oct 2023 //
BUSINESSWIRE
Humanetics Publishes Positive Clinical Trial Results of BIO 300
19 Sep 2023 //
BUSINESSWIRE
Humanetics Awarded Contract From DoD to Develop Drug to Prevent Radiation Injury
06 Sep 2023 //
BUSINESSWIRE
Humanetics Announces Results from Data Monitoring Committee Review of PII Trial
15 Feb 2023 //
BUSINESSWIRE
Humanetics Corporation Presents at the MedInvest Oncology Investor Conference
16 Dec 2022 //
BUSINESSWIRE
Humanetics Corporation Publishes Phase 1 Trial Results for BIO 300 Oral Powder
15 Nov 2022 //
BUSINESSWIRE
Humanetics Presents at Annual International Radiation Research Society Meeting
25 Oct 2022 //
BUSINESSWIRE
Humanetics Receives FDA Clearance to Begin Studies in Second Oncology Indication
05 Oct 2022 //
BUSINESSWIRE
Thomas F. Jasper Joins Board at Humanetics
22 Sep 2022 //
BUSINESSWIRE
U.S. Department of Defense Awards $5.1 Million to Humanetics Corporation
21 Jun 2022 //
BUSINESSWIRE
Humanetics extends long Covid drug trial to more sites
19 May 2022 //
CLINICALTRIALSARENA
Humanetics Corporation Expands Long-Haul COVID-19 Trial to Additional Sites
18 May 2022 //
BUSINESSWIRE
Mr. D. W. Bryce, Former Joint Program Exec Officer at U.S. Department of Defense
13 Apr 2022 //
BUSINESSWIRE
Humanetics Corporation Adds Two New Experts to its Board
26 Oct 2021 //
BUSINESSWIRE
Humanetics Announces Results from Phase 1 Trial of BIO 300 Oral Powder
22 Sep 2021 //
BUSINESSWIRE
Humanetics Corporation’s BIO 300 Receives Fast Track Designation from FDA
24 Aug 2021 //
BUSINESSWIRE
Humanetics Corporation Receives Funding From Department of Defense
26 Jan 2021 //
BUSINESSWIRE
L. Nathan, M.D., Joins Board of Directors at Minneapolis-based Humanetics
15 Sep 2020 //
BIOSPACE
Humanetics Partners with Pharmaceutics International
20 Aug 2020 //
CONTRACTPHARMA
Humanetics Corporation and Pharmaceutics International Announce Partnership
19 Aug 2020 //
GLOBENEWSWIRE
Humanetics to study BIO 300 to treat Covid-19 patients
23 Jul 2020 //
CLINICALTRIALSARENA
